Medtronic wins CE mark for blood oxygenation system; Researchers develop advanced 'virtual' foot as treatment aid;

 @FierceMedDev: Tribogenics pulled in a $6.2M Series A round, to help develop portable X-ray sources for medical imaging. Release | Follow @FierceMedDev

 @MarkHFierce: Look at Teleflex, getting a 510(k) for a continuous peripheral nerve block catheter--a new anesthesia tool. Release | Follow @MarkHFierce

 @DamianFierce: Medtronic is making noise in India, appointing a new board member and committing $6M in grant money there. More | Follow @DamianFierce

> Medtronic ($MDT) obtained a CE mark in Europe for its new oxygenation system, designed to remove carbon dioxide from blood during open-heart surgery. Release

> As the device tax deadline gets closer, USA Today reminds us that some observers see the 2.3% excise tax as not hurting innovation or the discovery of new technologies in the least. Story

> Tribogenics closed a $6.2 million Series A round led by Founders Fund. The money will help fuel development of small, portable X-ray sources for medical imaging and other industries. Release

> GI Dynamics has expanded use of its EndoBarrier anti-obesity device to two new Australian clinics. Story

> Strand Diagnostics is rolling out a new product designed to protect breast biopsy patients from inaccurate diagnosis because biopsy samples are misidentified. Release

> Teleflex ($TFX) won 510(k) clearance for its latest continuous peripheral nerve block catheter, designed to be used for anesthesia and acute pain management. Release

> The FDA cleared Smiths Medical's new epidural administration safety system. Release

Biotech News

 @FierceBiotech: In case you missed it last week, check out our 2012 Fierce 15 report: Report | BPA 2012 Slideshow | Follow @FierceBiotech

 @JohnCFierce: Peregrine is now a penny stock company, down 85%. And somewhere lawyers are beginning a new day, aflutter with litigious thoughts. | Follow @JohnCFierce

 @RyanMFierce: Virtual R&D groups make sense in cases where a pharma might otherwise just pull the plug on R&D in a field like CNS. More | Follow @RyanMFierce

> Mallinckrodt swallows CNS Therapeutics' drug pipeline in $100M buyout. News

> Novo Nordisk boosts China R&D with $100M diabetes research project. Report

> Peregrine shares blasted after trial 'discrepancies' discredit lung cancer data. Article

Pharma News

 @FiercePharma: U.K.'s Rosemont Pharmaceuticals is up for sale. Value est. at £200M; specializes in liquid formulations--Sky NewsReport | Follow @FiercePharma

> Regeneron, Vertex, J&J score high in employer rankings. Item

> Questcor stock reels as feds eye Acthar marketing. News

> Warring Herceptin studies could cut treatment times--or boost them. More

> Moody's gives pharma a sigh of relief with 'Worst Is Over' outlook. Story

CRO News

> EU experts call for clinical trials to focus on the elderly. Report

> Big Pharmas unite to improve clinical development. Article

> CMOs move toward disposable manufacturing tech. More

> Covance taps big data outfit for diabetes R&D. Story

Biotech IT News

> Google VC unit angles for further life sciences investments. Article

> NYC startup Medikly caters to pharma interactions with docs. More

> Accelrys goes late-stage in R&D software game. Story

> AstraZeneca builds virtual neuroscience drug unit byte by byte. Report

And Finally... Researchers in Europe have developed an advanced virtual model of the human foot to enable treatment of foot-related injuries and illness. Story

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.